drugset / Trial / NCT01830920

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

NCT01830920 ↗

Phase 2 Completed 452 enrolled Thrasos Innovation, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether THR-184 when administered around the time of cardiac surgery that requires cardiopulmonary bypass can prevent or ameliorate the development of acute kidney injury.

Timeline

Start
2013-05
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject THR-184 Peptide — Intravenous

Indications